United Therapeutics (UTHR) Tops Q2 EPS by 22c
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $1.34, $0.22 better than the analyst estimate of $1.12. Revenue for the quarter came in at $225.6 million versus the consensus estimate of $213.33 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
